Wainright Analyst report

https://hcwco.bluematrix.com/sellsi...o&[email protected]&source=mail

Worth a read. One point that really caught my eye is in relation to FDA approval (page 2). Also, while taking valuations with a grain of salt, has a valuation of 16c based on breast cancer (phase 1b results) alone i.e. excludes AML, ovarian and PTX-100

" Of note, according to positive discussions with the FDA, Prescient is using pCR instead of PFS, which could be a

valuable endpoint for accelerated approval. There are multiple PI3K and Akt inhibitors in clinical trials; however, preliminary data, literature, and our due diligence suggest that PTX-200 therapy could be successful in HTR BCa, where others have faltered thus far".​